alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
```

[Congressional Bills 110th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5003 Introduced in House (IH)]

110th CONGRESS
  2d Session
                                H. R. 5003

      To extend the temporary suspension of duty on Tetramethrin.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                            January 16, 2008

Mrs. Tauscher introduced the following bill; which was referred to the 
                      Committee on Ways and Means

_______________________________________________________________________

                                 A BILL

 
      To extend the temporary suspension of duty on Tetramethrin.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. TETRAMETHRIN.

    (a) In General.--Heading 9902.24.34 of the Harmonized Tariff 
Schedule of the United States is amended by striking ``12/31/2009'' and 
inserting ``12/31/2011''.
    (b) Effective Date.--The amendment made by subsection (a) applies 
with respect to goods entered, or withdrawn from warehouse for 
consumption, on or after the 15th day after the date of the enactment 
of this Act.
                                 <all>
```
HODGE v. PROCTOR.

No. COA04-364.

Court of Appeals of North Carolina.

Filed March 15, 2005.

Certification Date April 4, 2005.

Appeal from the Guilford (02CVS1467).

Case reported without published opinion. Affirmed.
EXHIBIT
32.1





CERTIFICATION
      REQUIRED BY 18 U.S.C. SECTION 1350(AS
      ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF
      2002)





I,
Stephen G. Fendrich, as President and Chief Operating Officer of Simmons Company
(the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my
knowledge:





(1) the
Quarterly Report on Form 10-Q of the Company for the quarter ended September 27,
2008 (the “Report”), being filed with the U.S. Securities and Exchange
Commission on the date hereof, fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934, as amended;
and





(2) the
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company.





Date:  June
10, 2009     U/s/ Stephen G.
FendrichU


Name: Stephen G.
Fendrich


Title: President and
Chief Operating Officer








A signed
original of this written statement required by Section 906 has been provided to
Simmons Company and will be retained by Simmons Company and furnished to the
Securities and Exchange Commission or its staff upon request.
I 

110TH CONGRESS 

1ST SESSION H. R. 4793 

To extend the suspension of duty on cyprodinil. 

IN THE HOUSE OF REPRESENTATIVES 

DECEMBER 18, 2007 

Mr. COBLE introduced the following bill; which was referred to the Committee 

on Ways and Means 

A BILL 

To extend the suspension of duty on cyprodinil. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. CYPRODINIL. 

4 (a) IN GENERAL.—Heading 9902.02.08 of the Har5 monized Tariff Schedule of the United States (relating to 

6 cyprodinil) is amended by striking ‘‘12/31/2009’’ and by 

7 inserting ‘‘12/31/2011’’. 

8 (b) EFFECTIVE DATE.—The amendment made by 

9 subsection (a) applies to goods entered, or withdrawn from 

10 warehouse for consumption, on or after the 15th day after 

11 the date of the enactment of this Act. 

Æ 


bajohnson on PROD1PC69 with BILLS
**Exhibit12.1**

**Hospira,Inc.**

**Computationof Ratio of Earnings to Fixed Charges**

**(Unaudited)**

***(dollars in millions except ratios)***
| ** **                                                        | ** ** | **Three Months**        | ** ** |
|-------------------------------------------------------------------|------------|------------------------------|------------|
| ** **                                                        | ** ** | **Ended**                    | ** ** |
| ** **                                                        | ** ** | **March 31, 2007** | ** ** |
|                                                              |       |                         |       |
| Loss from Continuing  Operations Before Taxes                     |       | $                            | (29.4      | ) |
| Add (Subtract):                                                   |       |                         |       |
| One-third of rents                                                |       | 2.1                          |       |
| Interest on long-term  and short-term debt                        |       | 30.5                         |       |
| Interest capitalized,  net of amortization                        |       | 1.6                          |       |
|                                                              |       |                         |       |
| Earnings from  Continuing Operations                              |       | $                            | 4.8        |   |
|                                                              |       |                         |       |
| Fixed charges:                                                    |       |                         |       |
| One-third of rents                                                |       | 2.1                          |       |
| Interest on long-term  and short-term debt                        |       | 30.5                         |       |
| Interest capitalized                                              |       | 2.6                          |       |
|                                                              |       |                         |       |
| Fixed Charges  from Continuing Operations                         |       | $                            | 35.2       |   |
|                                                              |       |                         |       |
| Ratio of Earnings to Fixed Charges from Continuing Operations (1) |       | —                       |       |

 

----

(1) Indicates an earnings to fixed chargesdeficiency of $30.4 million.

For purposes of computingthis ratio, “earnings” consist of income from continuing operations beforetaxes, one-third of rents (deemed by Hospira to be representative of theinterest factor inherent in rents), interest expense and interest capitalized,net of amortization.  “Fixed charges”consist of one-third of rents, interest expense as reported in the Company’sconsolidated financial statements and interest capitalized.

----
STATE v. ANDREWS.

No. COA04-1369.

Court of Appeal of North Carolina

Filed August 2, 2005.

Certification Date August 22, 2005.

Appeal from the New Hanover (02CRS20177)

Case reported without published opinion No error.
Order entered September 29, 2015

In The

Court of Appeals 

Fifth District of Texas at Dallas 

No. 05-15-01106-CV

IN RE MAURICIO ANTONIO CABRERA, Relator

Original Proceeding from the 195th Judicial District Court

Dallas County, Texas

Trial Court Cause No. F-1057867-N

ORDER

Before Justices Lang-Miers, Stoddart and Whitehill

Based on the Court’s opinion of this date, we DISMISS the petition for writ of 

mandamus. We ORDER relator to bear the costs of this original proceeding.

/Elizabeth Lang-Miers/

ELIZABETH LANG-MIERS

JUSTICE
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Literature Selection Technical Review Committee. The meeting is devoted to the review and evaluation of journals for potential indexing by the National Library of Medicine and will be closed to the public in accordance with the provisions set forth in section 552b(c)(9)(B), Title 5 U.S.C., as amended. Premature disclosure of the titles of the journals as potential titles to be indexed by the National Library of Medicine, the discussions, and the presence of individuals associated with these publications could significantly frustrate the review and evaluation of individual journals.

*Name of Committee:*                         Literature Selection Technical Review Committee.                    

*Date:*                         October 27-28, 2022.                    

*Time:*                         9:30 a.m. to 5:00 p.m.                    

*Agenda:*                         To review and evaluate journals as potential titles to be indexed by the National Library of Medicine.                    

*Place:*                         Virtual Meeting.                    

*Contact Person:*                         Dianne Babski, Associate Director, Division of Library Operations, National Library of Medicine, 8600 Rockville Pike, Building 38, Room 4S404, Bethesda, MD 20894, 301-827-4729,                         *babskid@mail.nih.gov.*      ( print page 39539)    

(Catalogue of Federal Domestic Assistance Program No. 93.879, Medical Library Assistance, National Institutes of Health, HHS).

Dated: June 28, 2022.

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022-14129 Filed 6-30-22; 8:45 am]

BILLING CODE 4140-01-P
EXHIBIT 32


                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Premier Alliance Group, Inc., a
Delaware corporation (the "Company") on Form 10-QSB for the period ended June
30, 2006, as filed with the Securities and Exchange Commission on the date
hereof (the "Report"), Mark S. Elliott, Acting Chief Executive and Financial
Officer of the Company, certifies to the best of his knowledge, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that:

         (1)   The Report fully complies with the  requirements of Section 13(a)
               or 15(d) of the Securities Exchange Act of 1934; and

         (2)   The information  contained in the Report fairly presents,  in all
               material  respects,   the  financial   condition  and  result  of
               operations of the Company.

A signed original of this written statement required by Section 906 has been
provided to Premier Alliance Group, Inc., and will be retained by Premier
Alliance Group, Inc. and furnished to the Securities and Exchange Commission or
its staff upon request.


  /s/ Mark S. Elliott
-----------------------
Mark S. Elliott
Acting Chief Executive and Financial Officer
August 10, 2006
# L_2016155EN.01000801.xml

| 14.6.2016 | EN | Official Journal of the European Union | L 155/8 |
| --- | --- | --- | --- |

14.6.2016

EN

Official Journal of the European Union

L 155/8

---

COMMISSION IMPLEMENTING REGULATION (EU) 2016/930

of 1 June 2016

entering a name in the register of protected designations of origin and protected geographical indications (Fogaça da Feira (PGI))

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EU) No 1151/2012 of the European Parliament and of the Council of 21 November 2012 on quality schemes for agricultural products and foodstuffs (1), and in particular Article 52(2) thereof,

Whereas:

| (1) | Pursuant to Article 50(2)(a) of Regulation (EU) No 1151/2012, Portugal's application to register the name ‘Fogaça da Feira’ was published in the Official Journal of the European Union (2). |
| --- | --- |

(1)

Pursuant to Article 50(2)(a) of Regulation (EU) No 1151/2012, Portugal's application to register the name ‘Fogaça da Feira’ was published in the Official Journal of the European Union (2).

| (2) | As no statement of opposition under Article 51 of Regulation (EU) No 1151/2012 has been received by the Commission, the name ‘Fogaça da Feira’ should therefore be entered in the register, |
| --- | --- |

(2)

As no statement of opposition under Article 51 of Regulation (EU) No 1151/2012 has been received by the Commission, the name ‘Fogaça da Feira’ should therefore be entered in the register,

HAS ADOPTED THIS REGULATION:

Article 1

The name ‘Fogaça da Feira’ (PGI) is hereby entered in the register.

The name specified in the first paragraph denotes a product in Class 2.3. Bread, pastry, cakes, confectionery, biscuits and other baker's wares in accordance with Annex XI to Commission Implementing Regulation (EU) No 668/2014 (3).

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 1 June 2016.

For the Commission,

On behalf of the President,

Phil HOGAN

Member of the Commission

---

(1)  
  OJ L 343, 14.12.2012, p. 1.

1

(2)  
  OJ C 58, 13.2.2016, p. 45.

2

(3)  Commission Implementing Regulation (EU) No 668/2014 of 13 June 2014 laying down rules for the application of Regulation (EU) No 1151/2012 of the European Parliament and of the Council on quality schemes for agricultural products and foodstuffs (OJ L 179, 19.6.2014, p. 36).

3

---
WILSON v. BELCO, INC.

No. COA04-578

North Carolina Court of Appeals

Filed May 17, 2005

Certification Date June 6, 2005

Appeal from Guilford (01CVS12724).

Case reported without published opinion. No error.
##### 



Exhibit 32.1


CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND
CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C.
SECTION 1350,


AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002


I, David G. Nance, certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that the
Annual Report of Introgen Therapeutics, Inc. on Form 10-K
for the fiscal year ended December 31, 2003 fully complies
with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934 and that information contained
in such Annual Report fairly presents in all material respects
the financial condition and results of operations of Introgen
Therapeutics, Inc.



| |                       
| | ----------------------
| | By: /s/ DAVID G. NANCE
| |                       



| |                     
| | --------------------
| | Name: David G. Nance

| |        |                        
| | ------ | -----------------------
| | Title: | Chief Executive Officer

I, James W. Albrecht, Jr., certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that the
Annual Report of Introgen Therapeutics, Inc. on Form 10-K
for the fiscal year ended December 31, 2003 fully complies
with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934 and that information contained
in such Annual Report fairly presents in all material respects
the financial condition and results of operations of Introgen
Therapeutics, Inc.



| |                               
| | ------------------------------
| | By: /s/ JAMES W. ALBRECHT, JR.
| |                               



| |                             
| | ----------------------------
| | Name: James W. Albrecht, Jr.

| |        |                        
| | ------ | -----------------------
| | Title: | Chief Financial Officer
---

**Exhibit 13 (b)**





CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002







I, Roy Wolvin, CFO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report on Form 20-F for the year ended December 31, 2008 of Nymox Pharmaceutical Corporation and filed with the Securities and Exchange Commission, fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934 and the information contained in such report fairly presents, in all material respects, the financial condition and results of operations on Nymox Pharmaceutical Corporation.





Date: March 13, 2009





/s/ Roy Wolvin

Roy Wolvin

Chief Financial Officer

Nymox Pharmaceutical Corporation







---
EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and in connection with the Quarterly Report on Form 10-Q of Paladin Realty Income Properties, Inc. (the Company) for the period ended September 30, 2008, as
filed with the Securities and Exchange Commission on the date hereof (the Report), the undersigned, the President, Chief Executive Officer and Director of the Company, certifies, to his knowledge, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



/s/    WHITNEY A.
GREAVESWhitney A. Greaves President and Chief Executive Officer (Principal Executive Officer)


November 10, 2008
NOTE : This order is nonprecedential.



# United States Court of Appeals

**for the Federal Circuit**

______________________

STX FINANCING, LLC,

Appellant

v.

KATHERINE K. VIDAL, Under Secretary of

Commerce for Intellectual Property and

Director of the United States Patent and

Trademark Office,

Intervenor

______________________

2022

- 1192

______________________

Appeal from the United States Patent and Trademark

Office, Trademark Trial and Appeal Board in No.

91240829

.

______________________

O R D E R

The parties having so agreed, it is ordered that:

(1) The proceeding is DISMISSED under Fed. R. App.

P. 42 (b).

(2) Each side s hall bear their own costs.

FOR THE COURT

April 15, 2022

Date /s/ Peter R. Marksteiner

Peter R. Marksteiner

Clerk of Court

ISSUED AS A MANDATE: April 15, 2022 Case: 22-1192 Document: 15 Page: 1 Filed: 04/15/2022
Exhibit 32.1

CERTIFICATION ACCOMPANYING FORM 10-Q REPORT  OF  REDDY ICE HOLDINGS, INC.  PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002  (CHAPTER 63, TITLE 18 U.S.C.
SS.SS. 1350(a) AND (b))

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chapter 63, Title 18 U.S.C. ss.ss. 1350(a) and (b)), the
undersigned hereby certifies that the Quarterly Report on Form 10-Q for the period ended March 31, 2010 of Reddy Ice Holdings, Inc. (the "Company") fully complies with
the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in such Report fairly presents, in all material respects, the
financial condition and results of operations of the Company.

Date:
April 22, 2010

/s/ GILBERT M. CASSAGNE Gilbert M. Cassagne,
Chief Executive Officer


The
foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chapter 63, Title 18 U.S.C. ss.ss. 1350(a) and (b)), is not
a part of the Form 10-Q to which it refers and is, to the extent permitted by law, provided by the above signatory to the extent of his knowledge.

A
signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed
form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and
Exchange Commission or its staff upon request.

---



QuickLinks
WAITE v. MEYERS.

No. COA04-1296.

Court of Appeal of North Carolina

Filed August 2, 2005.

Certification Date August 22, 2005.

Appeal from the NC Industrial Commission (I.C. #955034)

Case reported without published opinion Affirmed in part, reversed and remanded in part.
Diane Wilson BOWEN, Executrix of the Estate of Bruce Pickett Wilson, v. Pamela Y. MABRY, Executrix of the Estate of Josephine Downer Wilson.

No. 47PA03.

Supreme Court of North Carolina.

November 7, 2003.

Biesecker, Tripp, Sink & Fritts, by Max R. Rodden, Lexington, for plaintiff-appellee.

Michelle D. Reingold for defendant-appellant.

PER CURIAM.

DISCRETIONARY REVIEW IMPROVIDENTLY ALLOWED.
Exhibit 31.1
CERTIFICATIONS
I, Peter Weigand, certify that:
 1.  I have reviewed this quarterly report on Form 10-Q of Commerce Energy Group, Inc.;  2.  Based on my knowledge, this quarterly report does not contain any untrue statement of amaterial fact or omit to state a material fact necessary to make the statements made, inlight of the circumstances under which such statements were made, not misleading withrespect to the period covered by this quarterly report;  3.  Based on my knowledge, the financial statements, and other financial informationincluded in this quarterly report, fairly present in all material respects the financialcondition, results of operations and cash flows of the registrant as of, and for, theperiods presented in this quarterly report;  4.  The registrant’s other certifying officers and I are responsible for establishing andmaintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and15d-14) for the registrant and have:
 a)  designed such disclosure controls and procedures, or caused such disclosurecontrols and procedures to be designed under our supervision, to ensure that materialinformation relating to the registrant, including its consolidated subsidiaries, ismade known to us by others within those entities, particularly during the period inwhich this quarterly report is being prepared;  c)  evaluated the effectiveness of the registrant’s disclosure controls andprocedures and presented in this report our conclusions about the effectiveness of thedisclosure controls and procedures, as of the end of the period covered by this reportbased on such evaluation; and  d)  disclosed in this report any change in the registrant’s internal control overfinancial reporting that occurred during the registrant’s most recent fiscal quarterthat has materially affected, or is reasonably likely to materially affect theregistrant’s internal controls over financial reporting; and
 5.  The registrant’s other certifying officers and I have disclosed, based on our mostrecent evaluation of internal control over financial reporting, to the registrant’sauditors and the audit committee of registrant’s board of directors (or persons performingthe equivalent functions):
 a)  all significant deficiencies and material weaknesses in the design or operationof internal controls over financial reporting which are reasonably likely to adverselyaffect the registrant’s ability to record, process, summarize and report financialinformation; and  b)  any fraud, whether or not material, that involves management or other employeeswho have a significant role in the registrant’s internal controls over financialreporting.        Date: March 17, 2005 By:  /s/ PETER WEIGAND    PETER WEIGAND    President